



Global Urinary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-21	186	PDF

Single User	Multi User	Enterprise
USD 3,950	USD 5,925	USD 7,900

Description

The global Urinary Drugs market is projected to grow from US\$ million in 2026 to US\$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Urinary Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urinary Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Urinary Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Urinary Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urinary Drugs include Sanofi S.A., Pfizer Inc., GlaxosmithKline Plc., Bayer AG, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc. and Allergan Plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urinary Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urinary Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urinary Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urinary Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Urinary Drugs Segment by Company

- Sanofi S.A.
- Pfizer Inc.
- GlaxosmithKline Plc.

Bayer AG
Otsuka Pharmaceutical Co., Ltd.
Daiichi Sankyo Company Limited
Astellas Pharma Inc.
Allergan Plc.

Urinary Drugs Segment by Type

Oral
Injectables

Urinary Drugs Segment by Application

Clinic
Hospital
Home Care

Urinary Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urinary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Provides an overview of the Urinary Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2:

Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3:

Detailed analysis of Urinary Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6:

Sales of Urinary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7:

Revenue of Urinary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Concluding Insights of the report

Table of Contents

1 Market Overview

- 1.1 Product Definition
- 1.2 Global Urinary Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Urinary Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Urinary Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Urinary Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives

2 Global Urinary Drugs Market Dynamics

- 2.1 Urinary Drugs Industry Trends
- 2.2 Urinary Drugs Industry Drivers
- 2.3 Urinary Drugs Industry Opportunities and Challenges
- 2.4 Urinary Drugs Industry Restraints

3 Urinary Drugs Market by Manufacturers

- 3.1 Global Urinary Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Urinary Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Urinary Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Urinary Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Urinary Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Urinary Drugs Manufacturers, Product Type & Application
- 3.7 Global Urinary Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
 - 3.8.1 Global Urinary Drugs Market CR5 and HHI
 - 3.8.2 Global Top 5 and 10 Urinary Drugs Players Market Share by Revenue in 2025
 - 3.8.3 2025 Urinary Drugs Tier 1, Tier 2, and Tier 3

4 Urinary Drugs Market by Type

- 4.1 Urinary Drugs Type Introduction
 - 4.1.1 Oral
 - 4.1.2 Injectables
- 4.2 Global Urinary Drugs Sales by Type
 - 4.2.1 Global Urinary Drugs Sales by Type (2021 VS 2025 VS 2032)
 - 4.2.2 Global Urinary Drugs Sales by Type (2021-2032)
 - 4.2.3 Global Urinary Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Urinary Drugs Revenue by Type
 - 4.3.1 Global Urinary Drugs Revenue by Type (2021 VS 2025 VS 2032)
 - 4.3.2 Global Urinary Drugs Revenue by Type (2021-2032)
 - 4.3.3 Global Urinary Drugs Revenue Market Share by Type (2021-2032)

5 Urinary Drugs Market by Application

- 5.1 Urinary Drugs Application Introduction
 - 5.1.1 Clinic
 - 5.1.2 Hospital
 - 5.1.3 Home Care

5.2 Global Urinary Drugs Sales by Application

- 5.2.1 Global Urinary Drugs Sales by Application (2021 VS 2025 VS 2032)
 - 5.2.2 Global Urinary Drugs Sales by Application (2021-2032)
 - 5.2.3 Global Urinary Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Urinary Drugs Revenue by Application
- 5.3.1 Global Urinary Drugs Revenue by Application (2021 VS 2025 VS 2032)
 - 5.3.2 Global Urinary Drugs Revenue by Application (2021-2032)
 - 5.3.3 Global Urinary Drugs Revenue Market Share by Application (2021-2032)

6 Global Urinary Drugs Sales by Region

- 6.1 Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Urinary Drugs Sales by Region (2021-2032)
- 6.2.1 Global Urinary Drugs Sales by Region (2021-2026)
 - 6.2.2 Global Urinary Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.3.2 North America Urinary Drugs Sales by Country (2021-2032)
 - 6.3.3 U.S.
 - 6.3.4 Canada
 - 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.4.2 Europe Urinary Drugs Sales by Country (2021-2032)
 - 6.4.3 Germany
 - 6.4.4 France
 - 6.4.5 U.K.
 - 6.4.6 Italy
 - 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.5.2 Asia Pacific Urinary Drugs Sales by Country (2021-2032)
 - 6.5.3 China
 - 6.5.4 Japan
 - 6.5.5 South Korea
 - 6.5.6 Southeast Asia
 - 6.5.7 India
 - 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.6.2 South America, Middle East and Africa Urinary Drugs Sales by Country (2021-2032)
 - 6.6.3 Brazil
 - 6.6.4 South Africa
 - 6.6.5 Saudi Arabia
 - 6.6.6 Turkey
 - 6.6.6 Argentina
 - 6.6.6 UAE
 - 6.6.6 Egypt
 - 6.6.6 Chile
-

7 Global Urinary Drugs Revenue by Region

7.1 Global Urinary Drugs Revenue by Region

7.1.1 Global Urinary Drugs Revenue by Region: 2021 VS 2025 VS 2032

7.1.2 Global Urinary Drugs Revenue by Region (2021-2026)

7.1.3 Global Urinary Drugs Revenue by Region (2027-2032)

7.1.4 Global Urinary Drugs Revenue Market Share by Region (2021-2032)

7.2 North America

7.2.1 North America Urinary Drugs Revenue (2021-2032)

7.2.2 North America Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032

7.3 Europe

7.3.1 Europe Urinary Drugs Revenue (2021-2032)

7.3.2 Europe Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032

7.4 Asia-Pacific

7.4.1 Asia-Pacific Urinary Drugs Revenue (2021-2032)

7.4.2 Asia-Pacific Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032

7.5 South America, Middle East and Africa

7.5.1 South America, Middle East and Africa Urinary Drugs Revenue (2021-2032)

7.5.2 South America, Middle East and Africa Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032

8 Company Profiles

8.1 Sanofi S.A.

8.1.1 Sanofi S.A. Company Information

8.1.2 Sanofi S.A. Business Overview

8.1.3 Sanofi S.A. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.1.4 Sanofi S.A. Urinary Drugs Product Portfolio

8.1.5 Sanofi S.A. Recent Developments

8.2 Pfizer Inc.

8.2.1 Pfizer Inc. Company Information

8.2.2 Pfizer Inc. Business Overview

8.2.3 Pfizer Inc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.2.4 Pfizer Inc. Urinary Drugs Product Portfolio

8.2.5 Pfizer Inc. Recent Developments

8.3 GlaxosmithKline Plc.

8.3.1 GlaxosmithKline Plc. Company Information

8.3.2 GlaxosmithKline Plc. Business Overview

8.3.3 GlaxosmithKline Plc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.3.4 GlaxosmithKline Plc. Urinary Drugs Product Portfolio

8.3.5 GlaxosmithKline Plc. Recent Developments

8.4 Bayer AG

8.4.1 Bayer AG Company Information

8.4.2 Bayer AG Business Overview

8.4.3 Bayer AG Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.4.4 Bayer AG Urinary Drugs Product Portfolio

8.4.5 Bayer AG Recent Developments

8.5 Otsuka Pharmaceutical Co., Ltd.

8.5.1 Otsuka Pharmaceutical Co., Ltd. Company Information

8.5.2 Otsuka Pharmaceutical Co., Ltd. Business Overview

8.5.3 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.5.4 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio

8.5.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments

8.6 Daiichi Sankyo Company Limited

8.6.1 Daiichi Sankyo Company Limited Company Information

8.6.2 Daiichi Sankyo Company Limited Business Overview

8.6.3 Daiichi Sankyo Company Limited Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.6.4 Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio

8.6.5 Daiichi Sankyo Company Limited Recent Developments

8.7 Astellas Pharma Inc.

8.7.1 Astellas Pharma Inc. Company Information

8.7.2 Astellas Pharma Inc. Business Overview

8.7.3 Astellas Pharma Inc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.7.4 Astellas Pharma Inc. Urinary Drugs Product Portfolio

8.7.5 Astellas Pharma Inc. Recent Developments

8.8 Allergan Plc.

8.8.1 Allergan Plc. Company Information

8.8.2 Allergan Plc. Business Overview

8.8.3 Allergan Plc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)

8.8.4 Allergan Plc. Urinary Drugs Product Portfolio

8.8.5 Allergan Plc. Recent Developments

9 Value Chain and Sales Channels Analysis

9.1 Urinary Drugs Value Chain Analysis

9.1.1 Urinary Drugs Key Raw Materials

9.1.2 Raw Materials Key Suppliers

9.1.3 Manufacturing Cost Structure

9.1.4 Urinary Drugs Production Mode & Process

9.2 Urinary Drugs Sales Channels Analysis

9.2.1 Direct Comparison with Distribution Share

9.2.2 Urinary Drugs Distributors

9.2.3 Urinary Drugs Customers

10 Concluding Insights

11 Appendix

11.1 Reasons for Doing This Study

11.2 Research Methodology

11.3 Research Process

11.4 Authors List of This Report

11.5 Data Source

11.5.1 Secondary Sources

11.5.2 Primary Sources

11.6 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Urinary Drugs Industry Trends
- Table 2: Urinary Drugs Industry Drivers
- Table 3: Urinary Drugs Industry Opportunities and Challenges
- Table 4: Urinary Drugs Industry Restraints
- Table 5: Global Urinary Drugs Revenue by Manufacturers (US\$ Million) & (2021-2026)
- Table 6: Global Urinary Drugs Revenue Market Share by Manufacturers (2021-2026)
- Table 7: Global Urinary Drugs Sales by Manufacturers (k tons) & (2021-2026)
- Table 8: Global Urinary Drugs Sales Market Share by Manufacturers
- Table 9: Global Urinary Drugs Average Sales Price (US\$/ton) of Manufacturers (2021-2026)
- Table 10: Global Urinary Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- Table 11: Global Urinary Drugs Key Manufacturers Manufacturing Sites & Headquarters
- Table 12: Global Urinary Drugs Manufacturers, Product Type & Application
- Table 13: Global Urinary Drugs Manufacturers Establishment Date
- Table 14: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15: Global Urinary Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
- Table 16: Major Manufacturers of Oral
- Table 17: Major Manufacturers of Injectables
- Table 18: Global Urinary Drugs Sales by Type 2021 VS 2025 VS 2032 (k tons)
- Table 19: Global Urinary Drugs Sales by Type (2021-2026) & (k tons)
- Table 20: Global Urinary Drugs Sales by Type (2027-2032) & (k tons)
- Table 21: Global Urinary Drugs Sales Market Share by Type (2021-2026)
- Table 22: Global Urinary Drugs Sales Market Share by Type (2027-2032)
- Table 23: Global Urinary Drugs Revenue by Type 2021 VS 2025 VS 2032 (k tons)
- Table 24: Global Urinary Drugs Revenue by Type (2021-2026) & (k tons)
- Table 25: Global Urinary Drugs Revenue by Type (2027-2032) & (k tons)
- Table 26: Global Urinary Drugs Revenue Market Share by Type (2021-2026)
- Table 27: Global Urinary Drugs Revenue Market Share by Type (2027-2032)
- Table 28: Major Manufacturers of Clinic
- Table 29: Major Manufacturers of Hospital
- Table 30: Major Manufacturers of Home Care
- Table 31: Global Urinary Drugs Sales by Application 2021 VS 2025 VS 2032 (k tons)
- Table 32: Global Urinary Drugs Sales by Application (2021-2026) & (k tons)
- Table 33: Global Urinary Drugs Sales by Application (2027-2032) & (k tons)
- Table 34: Global Urinary Drugs Sales Market Share by Application (2021-2026)
- Table 35: Global Urinary Drugs Sales Market Share by Application (2027-2032)
- Table 36: Global Urinary Drugs Revenue by Application 2021 VS 2025 VS 2032 (k tons)
- Table 37: Global Urinary Drugs Revenue by Application (2021-2026) & (k tons)
- Table 38: Global Urinary Drugs Revenue by Application (2027-2032) & (k tons)
- Table 39: Global Urinary Drugs Revenue Market Share by Application (2021-2026)
- Table 40: Global Urinary Drugs Revenue Market Share by Application (2027-2032)
- Table 41: Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons)
- Table 42: Global Urinary Drugs Sales by Region (2021-2026) & (k tons)
- Table 43: Global Urinary Drugs Sales Market Share by Region (2021-2026)
- Table 44: Global Urinary Drugs Sales Forecasted by Region (2027-2032) & (k tons)
- Table 45: Global Urinary Drugs Sales Forecasted Market Share by Region (2027-2032)
- Table 46: North America Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons)
- Table 47: North America Urinary Drugs Sales by Country (2021-2026) & (k tons)
- Table 48: North America Urinary Drugs Sales by Country (2027-2032) & (k tons)
- Table 49: Europe Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons)
- Table 50: Europe Urinary Drugs Sales by Country (2021-2026) & (k tons)
- Table 51: Europe Urinary Drugs Sales by Country (2027-2032) & (k tons)
- Table 52: Asia Pacific Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons)
- Table 53: Asia Pacific Urinary Drugs Sales by Country (2021-2026) & (k tons)
- Table 54: Asia Pacific Urinary Drugs Sales by Country (2027-2032) & (k tons)
- Table 55: South America, Middle East and Africa Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k

- tons)
- Table 56: South America, Middle East and Africa Urinary Drugs Sales by Country (2021-2026) & (k tons)
 - Table 57: South America, Middle East and Africa Urinary Drugs Sales by Country (2027-2032) & (k tons)
 - Table 58: Global Urinary Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
 - Table 59: Global Urinary Drugs Revenue by Region (2021-2026) & (US\$ Million)
 - Table 60: Global Urinary Drugs Revenue by Region (2027-2032) & (US\$ Million)
 - Table 61: Global Urinary Drugs Revenue Market Share by Region (2021-2026)
 - Table 62: Global Urinary Drugs Revenue Market Share by Region (2027-2032)
 - Table 63: Sanofi S.A. Company Information
 - Table 64: Sanofi S.A. Business Overview
 - Table 65: Sanofi S.A. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 66: Sanofi S.A. Urinary Drugs Product Portfolio
 - Table 67: Sanofi S.A. Recent Development
 - Table 68: Pfizer Inc. Company Information
 - Table 69: Pfizer Inc. Business Overview
 - Table 70: Pfizer Inc. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 71: Pfizer Inc. Urinary Drugs Product Portfolio
 - Table 72: Pfizer Inc. Recent Development
 - Table 73: GlaxosmithKline Plc. Company Information
 - Table 74: GlaxosmithKline Plc. Business Overview
 - Table 75: GlaxosmithKline Plc. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 76: GlaxosmithKline Plc. Urinary Drugs Product Portfolio
 - Table 77: GlaxosmithKline Plc. Recent Development
 - Table 78: Bayer AG Company Information
 - Table 79: Bayer AG Business Overview
 - Table 80: Bayer AG Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 81: Bayer AG Urinary Drugs Product Portfolio
 - Table 82: Bayer AG Recent Development
 - Table 83: Otsuka Pharmaceutical Co., Ltd. Company Information
 - Table 84: Otsuka Pharmaceutical Co., Ltd. Business Overview
 - Table 85: Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 86: Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio
 - Table 87: Otsuka Pharmaceutical Co., Ltd. Recent Development
 - Table 88: Daiichi Sankyo Company Limited Company Information
 - Table 89: Daiichi Sankyo Company Limited Business Overview
 - Table 90: Daiichi Sankyo Company Limited Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 91: Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio
 - Table 92: Daiichi Sankyo Company Limited Recent Development
 - Table 93: Astellas Pharma Inc. Company Information
 - Table 94: Astellas Pharma Inc. Business Overview
 - Table 95: Astellas Pharma Inc. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 96: Astellas Pharma Inc. Urinary Drugs Product Portfolio
 - Table 97: Astellas Pharma Inc. Recent Development
 - Table 98: Allergan Plc. Company Information
 - Table 99: Allergan Plc. Business Overview
 - Table 100: Allergan Plc. Urinary Drugs Sales (k tons), Price (US\$/ton), Revenue (US\$ Million) and Gross Margin (2021-2026)
 - Table 101: Allergan Plc. Urinary Drugs Product Portfolio
 - Table 102: Allergan Plc. Recent Development
 - Table 103: Key Raw Materials
 - Table 104: Raw Materials Key Suppliers
 - Table 105: Urinary Drugs Distributors List
 - Table 106: Urinary Drugs Customers List
 - Table 107: Research Programs/Design for This Report
 - Table 108: Authors List of This Report
 - Table 109: Secondary Sources
 - Table 110: Primary Sources

List of Figures:

- Figure 1: Urinary Drugs Product Image

- Figure 2: Global Urinary Drugs Market Size (US\$ Million), 2021 VS 2025 VS 2032
- Figure 3: Global Urinary Drugs Market Size (2021-2032) & (US\$ Million)
- Figure 4: Global Urinary Drugs Sales (2021-2032) & (k tons)
- Figure 5: Global Urinary Drugs Average Price (US\$/ton) & (2021-2032)
- Figure 6: Global Top 5 and 10 Urinary Drugs Players Market Share by Revenue in 2025
- Figure 7: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 8: Oral Image
- Figure 9: Injectables Image
- Figure 10: Global Urinary Drugs Sales by Type (2021 VS 2025 VS 2032) & (k tons)
- Figure 11: Global Urinary Drugs Sales Market Share 2021 VS 2025 VS 2032
- Figure 12: Global Urinary Drugs Sales Market Share by Type (2021-2032)
- Figure 13: Global Urinary Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k tons)
- Figure 14: Global Urinary Drugs Revenue Market Share 2021 VS 2025 VS 2032
- Figure 15: Global Urinary Drugs Revenue Market Share by Type (2021-2032)
- Figure 16: Clinic Image
- Figure 17: Hospital Image
- Figure 18: Home Care Image
- Figure 19: Global Urinary Drugs Sales by Application (2021 VS 2025 VS 2032) & (k tons)
- Figure 20: Global Urinary Drugs Sales Market Share 2021 VS 2025 VS 2032
- Figure 21: Global Urinary Drugs Sales Market Share by Application (2021-2032)
- Figure 22: Global Urinary Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k tons)
- Figure 23: Global Urinary Drugs Revenue Market Share 2021 VS 2025 VS 2032
- Figure 24: Global Urinary Drugs Revenue Market Share by Application (2021-2032)
- Figure 25: North America Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 26: North America Urinary Drugs Sales Market Share by Country (2021-2032)
- Figure 27: U.S. Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 28: Canada Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 29: Mexico Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 30: Europe Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 31: Europe Urinary Drugs Sales Market Share by Country (2021-2032)
- Figure 32: Germany Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 33: France Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 34: U.K. Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 35: Italy Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 36: Netherlands Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 37: Asia Pacific Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 38: Asia Pacific Urinary Drugs Sales Market Share by Country (2021-2032)
- Figure 39: China Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 40: Japan Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 41: South Korea Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 42: Southeast Asia Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 43: India Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 44: Australia Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 45: South America, Middle East and Africa Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 46: South America, Middle East and Africa Urinary Drugs Sales Market Share by Country (2021-2032)
- Figure 47: Brazil Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 48: South Africa Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 49: Saudi Arabia Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 50: Turkey Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 51: Argentina Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 52: UAE Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 53: Egypt Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 54: Chile Urinary Drugs Sales and Growth Rate (2021-2032) & (k tons)
- Figure 55: Global Urinary Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 56: Global Urinary Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032
- Figure 57: North America Urinary Drugs Revenue (2021-2032) & (US\$ Million)
- Figure 58: North America Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 59: Europe Urinary Drugs Revenue (2021-2032) & (US\$ Million)
- Figure 60: Europe Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 61: Asia-Pacific Urinary Drugs Revenue (2021-2032) & (US\$ Million)
- Figure 62: Asia-Pacific Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 63: South America, Middle East and Africa Urinary Drugs Revenue (2021-2032) & (US\$ Million)
- Figure 64: South America, Middle East and Africa Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 65: Urinary Drugs Value Chain
- Figure 66: Manufacturing Cost Structure

- Figure 67: Urinary Drugs Production Mode & Process
- Figure 68: Direct Comparison with Distribution Share
- Figure 69: Distributors Profiles
- Figure 70: Years Considered
- Figure 71: Research Process
- Figure 72: Key Executives Interviewed